After a successful and highly productive first grant period, the Oregon Clinical and Translational Research Institute (OCTRI) is well positioned to have greater impact in the next grant period. OCTRI's goals are:
Specific Aim 1. Generate sustained OHSU and KPCHR research growth and productivity across the spectrum of translational science.
Specific Aim 2. Translate new biomedical knowledge into widespread advances in human health and healthcare reform.
Specific Aim 3. Create a regional consortium for clinical and translational research.
Specific Aim 4. Expand the impact of the strong OCTRI educational curriculum, develop an institution-wide, coordinated career development process that builds on the strengths of existing programs, and extend it throughout the region and nationally.
Specific Aim 5. Enhance key infrastructure programs to support local and regional clinical and translational research. These plans will build on major progress during the first grant period to further expand clinical and translational research, career development and benefits to human health. OCTRI will utilize a series of innovative partnerships to leverage CTSA support, expand its extensive collaborations with communities, and take advantage of a regional consortium of academic institutions working together to enhance translation. As a member of the CTSA Consortium, OCTRI will contribute unique expertise and resources to the combined effort to solve biomedical problems. Oregon Health and Science University and its partner institution Kaiser Permanente Center for Health Research have committed strong leadership support and substantial institutional commitment to OCTRI's continued mission.

Public Health Relevance

OCTRI will have a major influence on clinical and translational research at OHSU and KPCHR, and will increase their contributions to biomedical discovery. As the only academic medical center in Oregon, OHSU has a unique opportunity to catalyze translational research growth on a regional scale. Via its participation in the CTSA Consortium, OCTRI will advance national research productivity.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Training Award (TL1)
Project #
5TL1TR000129-10
Application #
8877321
Study Section
Special Emphasis Panel (ZRR1)
Program Officer
Rosemond, Erica
Project Start
2006-09-30
Project End
2016-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
10
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Jenkins, Chelsea; Luty, Samuel B; Maxson, Julia E et al. (2018) Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. Sci Signal 11:
Chow, Marilynn; Gao, Lina; MacManiman, Jason D et al. (2018) Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. Oncogene 37:5221-5232
Peters, Austin J; Villasana, Laura E; Schnell, Eric (2018) Ketamine Alters Hippocampal Cell Proliferation and Improves Learning in Mice after Traumatic Brain Injury. Anesthesiology 129:278-295
Wicher, Sarah A; Jacoby, David B; Fryer, Allison D (2017) Newly divided eosinophils limit ozone-induced airway hyperreactivity in nonsensitized guinea pigs. Am J Physiol Lung Cell Mol Physiol 312:L969-L982
Bannon, Amber E; Kent, Jason; Forquer, Isaac et al. (2017) Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. Clin Cancer Res 23:6733-6743
King, Carly J; Woodward, Josha; Schwartzman, Jacob et al. (2017) Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget 8:111084-111095
Feng, Zipei; Bethmann, Daniel; Kappler, Matthias et al. (2017) Multiparametric immune profiling in HPV- oral squamous cell cancer. JCI Insight 2:
Kalpathy-Cramer, Jayashree; Campbell, J Peter; Erdogmus, Deniz et al. (2016) Plus Disease in Retinopathy of Prematurity: Improving Diagnosis by Ranking Disease Severity and Using Quantitative Image Analysis. Ophthalmology 123:2345-2351
Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703
Campbell, J Peter; Kalpathy-Cramer, Jayashree; Erdogmus, Deniz et al. (2016) Plus Disease in Retinopathy of Prematurity: A Continuous Spectrum of Vascular Abnormality as a Basis of Diagnostic Variability. Ophthalmology 123:2338-2344

Showing the most recent 10 out of 14 publications